Recent Finacing
Recent Raise
TOLREMO is a Swiss biotech and ETH Zurich spin‑off developing a drug‑discovery platform and small‑molecule resistance‑preventing therapies, including oral CBP/p300 inhibitor TT125‑802 entering Phase I for solid tumors.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at TOLREMO therapeutics.
